Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C204H306N54O72 |
| Molecular Weight | 4666.9391 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 38 / 38 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC5=CC=C(O)C=C5)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN6C(=O)C=CC6=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC7=CNC=N7)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O
InChI
InChIKey=DJIGFNCGXOAXOW-WTPNCWHFSA-N
InChI=1S/C204H306N54O72/c1-17-100(12)166(200(325)240-128(51-66-163(289)290)180(305)232-127(50-65-162(287)288)185(310)253-143(93-259)199(324)238-120(43-56-147(209)266)181(306)248-139(86-149(211)268)191(316)234-119(42-55-146(208)265)176(301)227-117(40-53-144(206)263)174(299)229-121(44-59-156(275)276)177(302)225-114(33-24-26-69-205)172(297)247-138(85-148(210)267)192(317)237-123(46-61-158(279)280)178(303)228-118(41-54-145(207)264)175(300)230-124(47-62-159(281)282)182(307)242-131(78-97(6)7)187(312)241-130(170(214)295)77-96(4)5)255-197(322)133(80-99(10)11)244-183(308)126(49-64-161(285)286)236-190(315)137(84-108-92-217-95-223-108)251-201(326)168(102(14)19-3)256-196(321)132(79-98(8)9)243-173(298)115(34-25-27-70-218-153(272)94-330-76-75-329-74-72-219-152(271)68-73-258-154(273)57-58-155(258)274)239-203(328)169(103(15)260)257-198(323)134(81-105-36-38-109(262)39-37-105)245-193(318)140(87-150(212)269)249-194(319)141(88-151(213)270)252-202(327)167(101(13)18-2)254-186(311)129(52-67-164(291)292)233-171(296)116(35-28-71-220-204(215)216)226-195(320)142(89-165(293)294)250-189(314)136(83-107-91-222-113-32-23-21-30-111(107)113)246-184(309)125(48-63-160(283)284)231-179(304)122(45-60-157(277)278)235-188(313)135(224-104(16)261)82-106-90-221-112-31-22-20-29-110(106)112/h20-23,29-32,36-39,57-58,90-92,95-103,114-143,166-169,221-222,259-260,262H,17-19,24-28,33-35,40-56,59-89,93-94,205H2,1-16H3,(H2,206,263)(H2,207,264)(H2,208,265)(H2,209,266)(H2,210,267)(H2,211,268)(H2,212,269)(H2,213,270)(H2,214,295)(H,217,223)(H,218,272)(H,219,271)(H,224,261)(H,225,302)(H,226,320)(H,227,301)(H,228,303)(H,229,299)(H,230,300)(H,231,304)(H,232,305)(H,233,296)(H,234,316)(H,235,313)(H,236,315)(H,237,317)(H,238,324)(H,239,328)(H,240,325)(H,241,312)(H,242,307)(H,243,298)(H,244,308)(H,245,318)(H,246,309)(H,247,297)(H,248,306)(H,249,319)(H,250,314)(H,251,326)(H,252,327)(H,253,310)(H,254,311)(H,255,322)(H,256,321)(H,257,323)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H4,215,216,220)/t100-,101-,102-,103+,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,166-,167-,168-,169-/m0/s1
| Molecular Formula | C204H306N54O72 |
| Molecular Weight | 4666.9391 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 38 / 38 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 18:08:00 GMT 2025
by
admin
on
Tue Apr 01 18:08:00 GMT 2025
|
| Record UNII |
MG9PC54E43
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11556
Created by
admin on Tue Apr 01 18:08:00 GMT 2025 , Edited by admin on Tue Apr 01 18:08:00 GMT 2025
|
PRIMARY | INN | ||
|
1417179-66-8
Created by
admin on Tue Apr 01 18:08:00 GMT 2025 , Edited by admin on Tue Apr 01 18:08:00 GMT 2025
|
NON-SPECIFIC SUBSTITUTION | |||
|
DB15166
Created by
admin on Tue Apr 01 18:08:00 GMT 2025 , Edited by admin on Tue Apr 01 18:08:00 GMT 2025
|
PRIMARY | |||
|
MG9PC54E43
Created by
admin on Tue Apr 01 18:08:00 GMT 2025 , Edited by admin on Tue Apr 01 18:08:00 GMT 2025
|
PRIMARY | |||
|
300000038021
Created by
admin on Tue Apr 01 18:08:00 GMT 2025 , Edited by admin on Tue Apr 01 18:08:00 GMT 2025
|
PRIMARY | |||
|
134694278
Created by
admin on Tue Apr 01 18:08:00 GMT 2025 , Edited by admin on Tue Apr 01 18:08:00 GMT 2025
|
PRIMARY | |||
|
2395796-76-4
Created by
admin on Tue Apr 01 18:08:00 GMT 2025 , Edited by admin on Tue Apr 01 18:08:00 GMT 2025
|
PRIMARY | |||
|
C179096
Created by
admin on Tue Apr 01 18:08:00 GMT 2025 , Edited by admin on Tue Apr 01 18:08:00 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antiviral, Maleimide, Peptide; Mechanism of Action: HIV envelope protein gp41 inhibitor, HIV fusion inhibitor; Highest Development Phase: Phase III for HIV infections; Most Recent Events: 06 Jun 2016 Interim efficacy and safety data from the phase III TALENT trial in HIV infections released by Frontiers Biotechnologies, 06 Jun 2016 Frontier Biotechnologies announces intention to submit NDA to China Food and Drug Administration in 2016, 21 Mar 2016 Albuvirtide is still in phase III trials for HIV infections (Combination therapy
Treatment-experienced patients) in China (IV)
|